Quarterly ResultMay 5, 2026, 04:12 PM
Ultragenyx Q1 Revenue $136M; Reaffirms 2026 Guidance
AI Summary
Ultragenyx Pharmaceutical Inc. reported Q1 2026 total revenue of $136 million, a slight decrease from $139 million in Q1 2025, with a net loss of $185 million. The company reaffirmed its full year 2026 total revenue guidance of $730 million to $760 million and remains on track for profitability in 2027. Key clinical milestones include FDA acceptance of BLAs for DTX401 and UX111 with PDUFA dates in August and September 2026, respectively, and Phase 3 data for GTX-102 expected in the second half of 2026.
Key Highlights
- Q1 2026 total revenue was $136 million, compared to $139 million in Q1 2025.
- Q1 2026 net loss increased to $185 million, or $1.84 per share, from $151 million in Q1 2025.
- Reaffirmed full year 2026 total revenue guidance of $730 million to $760 million.
- Crysvita revenue was $93 million, Dojolvi $18 million, and Evkeeza $18 million in Q1 2026.
- Cash, cash equivalents, and marketable securities were $534 million as of March 31, 2026.
- DTX401 BLA for GSDIa accepted for Priority Review with PDUFA date of August 23, 2026.
- UX111 resubmitted BLA for MPS IIIA accepted for Priority Review with PDUFA date of September 19, 2026.
- GTX-102 Phase 3 data for Angelman syndrome expected in the second half of 2026.